scispace - formally typeset
B

Biao Jiang

Researcher at Chinese Academy of Sciences

Publications -  254
Citations -  3797

Biao Jiang is an academic researcher from Chinese Academy of Sciences. The author has contributed to research in topics: Catalysis & Medicine. The author has an hindex of 31, co-authored 227 publications receiving 3062 citations. Previous affiliations of Biao Jiang include Nanjing University of Science and Technology & South China Agricultural University.

Papers
More filters
Journal ArticleDOI

Zn(II)-Mediated Alkynylation−Cyclization of o-Trifluoroacetyl Anilines: One-Pot Synthesis of 4-Trifluoromethyl-Substituted Quinoline Derivatives

TL;DR: A novel efficient route to 4-trifluoromethyl-substituted quinoline derivatives through the Zn(II)-mediated alkynylation-cyclization of o- Trifluoroacetyl anilines is described.
Journal ArticleDOI

Highly Enantioselective Alkynylation of α-Keto Ester: An Efficient Method for Constructing a Chiral Tertiary Carbon Center

TL;DR: The asymmetric addition of terminal alkynes to alpha-keto ester was carried out using a catalytic amount of (1S,2S)-3-(tert-butyldimethylsilyloxyl)-2-N,N-(dimethylamino)-1-(p-nitrophenyl)-propane-1-ol to give the corresponding tertiary propargylic alcohols in high yields with up to 94% ee.
Journal ArticleDOI

Syntheses and biological activities of bis(3-indolyl)thiazoles, analogues of marine bis(indole)alkaloid nortopsentins.

TL;DR: The thiazole analogues of the marine bis(indole)alkaloid nortopsentins, 2,4-bis(3-indolyl)thiazoles, were synthesized using Hantzsch reaction between indole-3-thioamides and 3-(alpha-bromoacetyl)indoles as the key step, and these analogues showed potent cytotoxic activities against a variety of human cancer cell lines in vitro.
Journal ArticleDOI

Synthesis and cytotoxicity evaluation of novel indolylpyrimidines and indolylpyrazines as potential antitumor agents.

TL;DR: Novel indolylpyrimidines and indolylpyrazines have been synthesized as potential antitumor agents and displayed selective cytotoxic activity against IGROV1 tumor cell line with the GI(50) value below 0.01 microM.